YNP of ERA

Young Nephrologists’ Platform of the ERA - Leading European Nephrology. Join us to shape future nephrology!

[YNP of ERA @ynptweets]

Congratulations to the young investigator award winners!

[ERA - European Renal Association @ERAkidney]

🧵3/Young Investigators #ERA26

[ERA - European Renal Association @ERAkidney]

📣 ONLY FEW HOURS LEFT TO #ERA26

Read our Daily Congress Bulletin 👉 https://t.co/ROtwCmfiHy

[ERA - European Renal Association @ERAkidney]

💥 Your vote matters! ERA Full Active Members can vote for the ERA Ordinary Council member candidates until the start of the ERA Ordinary General Assembly (OGA), happening on:

📅 TOMORROW, 16:15 - 17:15 (BST)

Discover more 👉 https://t.co/w4uRJEqgLa

[ERA - European Renal Association @ERAkidney]

⏰ 2 DAYS TO #ERA26

💡 Where nephrology dares to think differently at the 63rd ERA Congress on June 3-6, 2026, both virtual and live in Glasgow.

🔎 Start now by checking out the Scientific Programme 👉 https://t.co/Iv7l81zrch

[ERA - European Renal Association @ERAkidney]

🗳️ Are you an ERA Full Active Member? The voting to elect the new ERA Ordinary Council Members is now open.

Vote now 👉 https://t.co/rtmZFbCr17

[ERA - European Renal Association @ERAkidney]

🆕 Join us for the 5th JSN and YNP (ERA) Joint Meeting!⁣
⁣
📆 Friday, May 22, 2026, 12:00-1:15 PM (CEST) / 7 PM - 8:15 PM (JST)⁣
⁣
📌 Topic: Differences in kidney dialysis / combined HD–PD - Perspectives from Japan and Europe
⁣
Register now 👉 https://t.co/mdefVzbSB0

[ERA - European Renal Association @ERAkidney]

📢 Don't forget to register for ERA Education - Kaunas 2026!

📆 Join us on September 24-25, 2026, in Kaunas, Lithuania, for the fourth ERA Education Meeting.

What you’ll get:
📚Educational sessions
🎓Certificate of attendance and EACCME®/UEMS credits

📍Registrations are reserved for ERA Members only.

Register now 👉 https://t.co/wIWcvSBJJo

[ERA - European Renal Association @ERAkidney]

📣 Save the date for the “Late Breaking Clinical Trials II” at #ERA26 on:⁣
📅 June 5, 11:15–12:45 (BST)

Discover our Scientific Programme 👉 https://t.co/Iv7l81zrch

[YNP of ERA @ynptweets]

Another #InContext is online!

Albuminuria as a surrogate endpoint in chronic #kidney disease👇🏻

https://t.co/Go2hpiamgL

@beaff26 @CKJsocial

@ERAkidney

[YNP of ERA @ynptweets]

Two #InContexts have been published in the April issue of @CKJsocial!

@eva_pella @PepaSolerR

https://t.co/awwraaDh3z

https://t.co/uy5EkMxzts

@ERAkidney

[YNP of ERA @ynptweets]

Today, do not miss it!

[ERA - European Renal Association @ERAkidney]

📢 Join us at the ERA e-seminar jointly organised with the @UEMSEurope Section of Nephrology: *ESENeph exam at European level*

📅 April 29, 2026 at 5:00 PM (CEST)

Register now 👉 https://t.co/kt1mK5MRKY

[YNP of ERA @ynptweets]

Do not forget to register for our Meet & Greet in Glasgow!

#ERA26 @ERAkidney

https://t.co/ZAo4okpVsJ

[ERA - European Renal Association @ERAkidney]

Recurrent IgAN after Transplantation

E-Seminar hosted by @ynptweets

Watch the full recording https://t.co/JaKkyTZBD5 (ERA members only)

Some highlights here

1st talk by Eleni Stamellou focused on pathophysiology, risk factors and prevention

recurrent IgA
🔵Common 5% at 5y, 10% at 10 y
🔵Higher with protocol biopsies-42% at 5y
🔵Early studies underestimated the impact on graft survival - more recent studies have HRs fo 2.04-3.44

Pathophysiology
🔵Mirrors native disease- galactose deficient IgA1 and 4 hit hypothesus
🔵Role of complement- C3 deposition almost universal, C4d is a strong predictor of graft loss

[YNP of ERA @ynptweets]

11/📩 Take-home message

👉🏻 Beyond renal and metabolic benefits, dapagliflozin shows a neutral effect on bone turnover and density over 12 months in non-diabetic CKD.

Read more about it in 
📄 https://t.co/FXRcLnLX9U

#CKDMBD #SGLT2i

[YNP of ERA @ynptweets]

1/ 🤔 Do SGLT2i impact CKD-MBD?

👀 Check out this RCT that explores the effect of Dapagliflozin on CKD-MBD on non-diabetic patients.

Mohamed Elshayeb is the YNP author
Thread 🧵by @jt_nephrology
@CKJsocial @ERAkidney

[YNP of ERA @ynptweets]

10/ 🚧 Limitations

•Small sample size and number of participants with eGFR < 30 ml/min/1.73m2
•Single-center, exploratory design
•Short follow-up for bone outcomes
•Limited evalutation microarchitectural skeletal effects